Nicholas Wealth LLC. Acquires 17,397 Shares of Hims & Hers Health, Inc. $HIMS

Nicholas Wealth LLC. raised its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 67.3% in the first quarter, Holdings Channel.com reports. The fund owned 43,265 shares of the company’s stock after acquiring an additional 17,397 shares during the quarter. Nicholas Wealth LLC.’s holdings in Hims & Hers Health were worth $898,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. Norges Bank bought a new stake in Hims & Hers Health in the fourth quarter worth $62,153,000. Invesco Ltd. increased its position in Hims & Hers Health by 62.7% during the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after buying an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. acquired a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $87,372,000. Finally, Marex Group plc raised its stake in shares of Hims & Hers Health by 162.2% in the 4th quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock valued at $78,562,000 after acquiring an additional 1,496,707 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HIMS. Barclays lifted their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, June 17th. JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $29.37.

Hims & Hers Health Stock Up 3.5%

Shares of NYSE:HIMS opened at $33.86 on Friday. The company has a market capitalization of $7.84 billion, a PE ratio of -376.27, a P/E/G ratio of 48.52 and a beta of 2.37. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company’s fifty day moving average is $27.94 and its 200-day moving average is $26.47.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.05 earnings per share for the current fiscal year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Investors are focusing on Hims’ growing obesity-drug opportunity as more employers cut coverage for expensive GLP-1 weight-loss drugs, potentially steering more patients toward cash-pay telehealth options. Hims’ obesity drug business may get boost as employers drop coverage
• Positive Sentiment: Novo Nordisk described Hims & Hers as one of its most “voluminous” telehealth partners, reinforcing confidence that the company is seeing meaningful demand tied to its weight-loss offering. HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
• Positive Sentiment: Commentary on Hims’ subscriber growth highlighted 2.6 million subscribers in Q1, up 9% year over year, suggesting the core business continues to expand. HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
• Neutral Sentiment: Multiple valuation articles comparing Hims & Hers with Omnicell (OMCL) frame HIMS as a potential value stock, but they do not appear to introduce a clear new catalyst. OMCL or HIMS: Which Is the Better Value Stock Right Now?
• Negative Sentiment: A Seeking Alpha piece downgraded the stock, arguing that fundamentals may not fully support the recent rebound, which could temper bullish sentiment. Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade)
• Negative Sentiment: Recent insider selling by Patrick Harrison Carroll may add a small overhang for investors watching management and insider confidence. Patrick Harrison Carroll Sells 23,726 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Insider Activity at Hims & Hers Health

In related news, Director David B. Wells bought 48,400 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the acquisition, the director owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This represents a 27.50% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 163,973 shares of company stock worth $4,859,194. 11.76% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.